Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge in $2.2B CNS Biopharma “Merger of Equals”

August 6, 2026

Healthcare Services

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to merge in a tax-free all-stock “merger of equals” transaction expected to create a diversified central nervous system biopharmaceutical leader. Under the deal, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, and Indivior shareholders will receive a $1.0 billion special cash dividend immediately prior to closing.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Ergomed Acquires ADAMAS Consulting Group

February 9, 2022

Healthcare Services

Ergomed plc has acquired ADAMAS Consulting Group Limited for a cash consideration of £25.6 million (enterprise value £24.2m), adding a specialist regulatory compliance and quality assurance capability to its pharmaceutical services offering. ADAMAS, which recorded £8.5m revenue and £1.8m adjusted EBITDA in 2021, will continue to operate independently with its senior management retained and is expected to be immediately accretive to Ergomed's earnings while expanding the Group's global reach.

Alexion Pharmaceuticals Acquires Portola Pharmaceuticals

May 5, 2020

Biotechnology

Alexion Pharmaceuticals agreed to acquire Portola Pharmaceuticals in a cash tender offer at $18.00 per share to add Portola’s Factor Xa inhibitor reversal agent Andexxa and diversify Alexion’s commercial portfolio beyond its complement franchise. The transaction, unanimously approved by both boards, was expected to close in the third quarter of 2020 and will be funded with Alexion’s cash on hand.